The prognosis of patients with metastatic colorectal carcinoma (CRC) has improved substantially over the last two decades. Longer patient survival comes at a price of more complications, including second primary neoplasms and metastases at unusual sites.
Method
Retrospective chart review.
Results
We present 4 patients with metastatic CRC who developed kidney tumors. In 2 cases, partial nephrectomy or nephrectomy was performed for second primary renal cell carcinoma. The patients survived 2.5 and more than 6 years after kidney surgery. In the other 2 patients the kidney tumors were diagnosed as CRC metastases, histologically verified in one case; these two patients died within two years of diagnosis of kidney involvement.
Conclusion
The diagnostic approach to kidney tumors in CRC patients should include a biopsy because only patients with primary renal cell carcinoma and selected patients with metastatic CRC benefit from nephrectomy.
GrotheyA., SargentD., GoldbergR.M., SchmollH.J.: Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol, 22: 1209–1214, 2004.
2.
KoumarianouA.A., VernonC.C.: Second primary renal cell carcinomas following solid tumors. Four case reports and review of the literature. Tumori, 84: 600–602, 1998.
3.
HoarS.K., WilsonJ., BlotW.J., McLauglinJ.K., WinnD.M., KantorA.F.Second cancer following cancer of the digestive system in Connecticut, 1935–82. Natl Cancer Inst Monogr, 68: 49–82, 1985.
4.
FurákJ., TrojánI., SzökeT., WolfárdA., NagyE., NemetuI., TislaviczL., LázárG.: Lung cancer as a second primary malignant tumor: prognostic values after surgical resection. Interact Cardiovasc Thorac Surg, 7: 50–53, 2008.
5.
RabbaniF., ReuterV.E., KatzJ., RussoP.: Second primary malignacies associated with renal cell carcinoma: influence of histologic type. Urology, 56: 399–403, 2000.
6.
BeislandC., TalleraasO., BakkeA., NorsteinJ.: Multiple primary malignancies in patients with renal cell carcinoma: a national population-based cohort study. BJU Int, 97: 698–702, 2006.
WyczolkowskiM., KlimaW., BiedaW., WalasK.: Spontaneous regression of hepatic metastases after nephrectomy and metastasectomy of renal cell carcinoma. Urol Int, 66: 119–120, 2001.
9.
PapacR.J., Poo-HwuW.J.: Renal cell carcinoma: A paradigm of lanthanic disease. Am J Clin Oncol, 22: 223–231, 1999.
10.
BanksR.E., TirukondaP., TaylorC., HornigoldN., AstutiD., CohenD., MaherE.R., StanleyA.J., HarndenP., JoyceA., KnowlesM., SelbyP.J.: Genetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res, 66: 2000–2011, 2006.
11.
JulianovA., StoyanovH., KarashmalakovA.: Late renal metastasis from sigmoid adenocarcinoma. Lancet Oncol, 5: 726, 2004.
12.
BrambillaE., HeckA.A., CaoJ.G., ToniazzoG.T., PetteffiL.: Isolated renal metastasis after colon cancer. Can J Urol, 14: 3649–3650, 2007.
13.
WaleczekH., WenteM.N., KoziankaJ.: Complex pattern of colon cancer recurrence including a kidney metastasis: a case report. World J Gastroenterol, 11: 5571–5572, 2005.
14.
AksuG., FaydaM., SakarB., KapranY.: Colon cancer with isolated metastasis to the kidney at the time of initial diagnosis. Int J Gastrointest Cancer, 34: 73–77, 2003.
15.
MotzerR.J., MazumdarM., BacikJ., BergW., AmsterdamA., FerraraJ.: Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol, 17: 2530–2540, 1999.
16.
FlaniganR.C., SalmonS.E., BlumensteinB.A., BearmanS.I., RoyV., McGrathP.C., CatonJ.R., MunshiN., CrawfordE.D.: Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med, 345: 1655–1659, 2001.
17.
MickischG.H.J., GarinA., van PoppelH., de PrijckL., SylvesterR.: Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet, 358: 966–970, 2001.
18.
LokichJ.: Spontaneous regression of metastatic renal cancer: case report and literature review. Am J Clin Oncol, 20: 416–418, 1997.
19.
EscudierB., PluzanskaA., KoralewskiP., RavaudA., BracardaS., SzczylikC., ChevreauC., FilipekM., MelicharB., BajjettaE., GorbunovaE., BayJ.O., BodrogiI., Jagiello-GruszfeldA., MooreN.: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet, 370: 2103–2111, 2007.
20.
HurwitzH., FebrenbacherL., NovotnyW., CartwrightT., HainsworthJ., HeimW., BerlinJ., BaronA., GriffingS., HolmgrenE., FerraraN., FyfeG., RogersB., RossR., KabbinavarF.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med, 350: 2335–2342, 2004.
21.
GiantonioB.J., CatalanoP.J., MeropolN.J., O'DwyerP.J., MitchellE.P., AlbertsS.R., SchwartzM.A.: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group study E3200. J Clin Oncol, 25: 1539–1544, 2007.
